Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis.

Ronen ArbelEnis AboalhasanAriel HammermanJoseph Azuri

Published in: Clinical drug investigation (2020)

Our findings suggest that empagliflozin prescribed for preventing CV death or hHF in T2DM patients seems to be cost saving compared to treatment with canagliflozin, and dapagliflozin.

Keyphrases

heart failure
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
adipose tissue
combination therapy
insulin resistance
smoking cessation